Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: Analysis of a normal Japanese population

Microbiology and Immunology

Volumn 51, Issue 5, 2007, Pages 507-517

  Akatsu, Hiroyasu ^a   Ishiguro, Masae ^a   Ogawa, Norihiro ^a   Kanesaka, Takeshi ^a   Okada, Noriko ^b   Yamamoto, Takayuki ^a   Campbell, William ^a   Okada, Hidechika ^a  

^a Fukushimura Hospital   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Enzyme linked immunosorbent assay (ELISA); Polymorphism; Pro carboxypeptidase R (proCPR); Thrombin activatable fibrinolysis inhibitor (TAFI)

Indexed keywords

ALANINE; ENZYME PRECURSOR; ISOLEUCINE; THREONINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; JAPANESE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

EID: 34249069829     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2007.tb03939.x     Document Type: Article

References (42)

1. Akatsu, H., Yamagata, H., Chen, Y., Miki, T., Kamino, K., Takeda, M., Campbell, W., Kondo, I., Kosaka, K., Yamamoto, T., and Okada, H. 2004. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction. Br. J. Haematol. 127: 440-447.
2. Bajzar, L., Manuel, R., and Nesheim, M.E. 1995. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270: 14477-14484.
3. Bajzar, L., Morser, J., and Nesheim, M. 1996. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271: 16603-16608.
4. Belew, M., Gerdin, B., Lindeberg, G., Porath, J., Saldeen, T., and Wallin, R. 1980. Structure-activity relationships of vasoactive peptides derived from fibrin or fibrinogen degraded by plasmin. Biochim. Biophys. Acta 621: 169-178.
5. Boffa, M.B., Hamill, J.D., Bastajian, N., Dillon, R., Nesheim, M.E., and Koschinsky, M.L. 2002. A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 277: 25329-25336.
6. Boffa, M.B., Hamill, J.D., Maret, D., Brown, D., Scott, M.L., Nesheim, M.E., and Koschinsky, M.L. 2003. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J. Biol. Chem. 278: 9250-9257.
7. Bokisch, V.A., and Muller-Eberhard, H.J. 1970. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49: 2427-2436.
8. Brouwers, G.J., Vos, H.L., Leebeek, F.W., Bulk, S., Schneider, M., Boffa, M., Koschinsky, M., van Tilburg, N.H., Nesheim, M.E., Bertina, R.M., and Gomez Garcia, E.B. 2001. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98: 1992-1993.
9. Campbell, W., and Okada, H. 1989. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem. Biophys. Res. Commun. 162: 933-939.
10. Campbell, W., Yonezu, K., Shinohara, T., and Okada, H. 1990. An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis. J. Lab. Clin. Med. 115: 610-612.
11. Campbell, W.D., Lazoura, E., Okada, N., and Okada, H. 2002. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol. Immunol. 46: 131-134.
12. Chetaille, P., Alessi, M.C., Kouassi, D., Morange, P.E., and Juhan-Vague, I. 2000. Plasma TAFI antigen variations in healthy subjects. Thromb. Haemost. 83: 902-905.
13. Cosman, F., Baz-Hecht, M., Cushman, M., Vardy, M.D., Cruz, J.D., Nieves, J.W., Zion, M., and Lindsay, R. 2005. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb. Res. 116: 1-13.
14. Eaton, D.L., Malloy, B.E., Tsai, S.P., Henzel, W., and Drayna, D. 1991. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266: 21833-21838.
15. Erdos, E.G., and Sloane, E.M. 1962. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 11: 585-592.
16. Franco, R.F., Fagundes, M.G., Meijers, J.C., Reitsma, P.H., Lourenco, D., Morelli, V., Maffei, F.H., Ferrari, I.C., Piccinato, C.E., Silva, W.A., Jr., and Zago, M.A. 2001. Identification of polymorphisms in the 5′- untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86: 510-517.
17. Guimaraes, A.H., van Tilburg, N.H., Vos, H.L., Bertina, R.M., and Rijken, D.C. 2004. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br. J. Haematol. 124: 659-665.
18. Hendriks, D., Scharpe, S., van Sande, M., and Lommaert, M.P. 1989. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 27: 277-285.
19. Hendriks, D., Wang, W., Scharpe, S., Lommaert, M.P., and van Sande, M. 1990. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim. Biophys. Acta 1034: 86-92.
20. Henry, M., Aubert, H., Morange, P.E., Nanni, I., Alessi, M.C., Tiret, L., and Juhan-Vague, I. 2001. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97: 2053-2058.
21. Juhan-Vague, I., Morange, P.E., Aubert, H., Henry, M., Aillaud, M.F., Alessi, M.C., Samnegard, A., Hawe, E., Yudkin, J., Margaglione, M., Di Minno, G., Hamsten, A., and Humphries, S.E. 2002. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler. Thromb. Vasc. Biol. 22: 867-873.
22. Juhan-Vague, I., Renucci, J.F., Grimaux, M., Morange, P.E., Gouvernet, J., Gourmelin, Y., and Alessi, M.C. 2000. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler. Thromb. Vasc. Biol. 20: 2156-2161.
23. Kostka, H., Kuhlisch, E., Schellong, S., and Siegert, G. 2003. Polymorphisms in the TAFI gene and the risk of venous thrombosis. Clin. Lab. 49: 645-647.
24. Morange, P.E., Henry, M., Frere, C., and Juhan-Vague, I. 2002. Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infection. Blood 99: 1878-1879.
25. Mosnier, L.O., Buijtenhuijs, P., Marx, P.F., Meijers, J.C., and Bouma, B.N. 2003. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 101: 4844-4846.
26. Mosnier, L.O., Meijers, J.C., and Bouma, B.N. 2001. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb. Haemost. 85: 5-11.
27. Ozeren, M., Karahan, S.C., Ozgur, M., Eminagaoglu, S., Unsal, M., Baytan, S., and Bozkaya, H. 2005. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1. Acta Obstet. Gynecol. Scand. 84: 987-991.
28. Post, M.S., Hendriks, D.F., Van Der Mooren, M.J., Van Baal, W.M., Leurs, J.R., Emeis, J.J., Kenemans, P., and Stehouwer, C.D. 2002. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women. J. Intern. Med. 251: 245-251.
29. Ravindranath, T.M., Goto, M., Demir, M., Tobu, M., Kujawski, M.F., Hoppensteadt, D., Samonte, V., Iqbal, O., Sayeed, M.M., and Fareed, J. 2004. Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats. Clin. Appl. Thromb. Hemost. 10: 379-385.
30. Santamaria, A., Martinez-Rubio, A., Borrell, M., Mateo, J., Ortin, R., and Fontcuberta, J. 2004. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89: 880-881.
31. Sato, T., Miwa, T., Akatsu, H., Matsukawa, N., Obata, K., Okada, N., Campbell, W., and Okada, H. 2000. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J. Immunol. 165: 1053-1058.
32. Schneider, M., Boffa, M., Stewart, R., Rahman, M., Koschinsky, M., and Nesheim, M. 2002. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J. Biol. Chem. 277: 1021-1030.
33. Schroeder, V., Chatterjee, T., Mehta, H., Windecker, S., Pham, T., Devantay, N., Meier, B., and Kohler, H.P. 2002. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb. Haemost. 88: 1020-1025.
34. Shinohara, T., Sakurada, C., Suzuki, T., Takeuchi, O., Campbell, W., Ikeda, S., Okada, N., and Okada, H. 1994. Pro-carboxypeptidase R cleaves bradykinin following activation. Int. Arch. Allergy Immunol. 103: 400-404.
35. Silveira, A., Schatteman, K., Goossens, F., Moor, E., Scharpe, S., Stromqvist, M., Hendriks, D., and Hamsten, A. 2000. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb. Haemost. 84: 364-368.
36. Tani, S., Akatsu, H., Ishikawa, Y., Okada, N., and Okada, H. 2003. Preferential detection of pro-carboxypeptidase R by enzyme-linked immunosorbent assay. Microbiol. Immunol. 47: 295-300.
37. Teger-Nilsson, A.C. 1968. Degradation of human fibrinopeptides A and B in blood serum in vitro. Acta Chem. Scand. 22: 3171-3182.
38. Tregouet, D.A., Aubert, H., Henry, M., Morange, P., Visvikis, S., Juhan-Vague, I., and Tiret, L. 2001. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum. Genet. 109: 191-197.
39. van Tilburg, N.H., Rosendaal, F.R., and Bertina, R.M. 2000. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95: 2855-2859.
40. Watanabe, R., Wada, H., Watanabe, Y., Sakakura, M., Nakasaki, T., Mori, Y., Nishikawa, M., Gabazza, E.C., Nobori, T., and Shiku, H. 2001. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb. Res. 104: 1-6.
41. Zhao, L., Morser, J., Bajzar, L., Nesheim, M., and Nagashima, M. 1998. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb. Haemost. 80: 949-955.
42. Zorio, E., Castello, R., Falco, C., Espana, F., Osa, A., Almenar, L., Aznar, J., and Estelles, A. 2003. Thrombinactivatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br. J. Haematol. 122: 958-965.